Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KeyCorp (KEY) vs GeneDx Holdings Corp (WGS) Price & Performance

GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

KeyCorp vs GeneDx Holdings Corp — how do they compare? KeyCorp trades at $22.72 (market cap $24.32B), while GeneDx Holdings Corp trades at $82.37 (market cap $2.44B). The key difference: KeyCorp is far larger — about 10× GeneDx Holdings Corp's market cap, and KeyCorp pays a 3.61% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

KEYWGS
Market Cap
$24.32B$2.44B
Sector
FinancialsTechnology
52-Week High
$23.99$167.51
52-Week Low
$16.78$34.51
Dividend Yield
3.61%
Enterprise Value
$2.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KeyCorp

KeyCorp (KEY) trades at $22.68, down 0.22% on the day, with a bearish technical signal but strong fundamental recovery. The company reported Q2 2026 EPS of $0.44, beating estimates, and shows robust revenue growth to $7.29B in 2025. Recent expansion includes the acquisition of Clearwater UK, enhancing its investment banking footprint.

The outlook is positive with a consensus price target of $29.41, representing significant upside. Risks include economic uncertainty impacting loan growth and net interest income. The stock offers a dividend yield supported by consistent payouts, with analyst sentiment strongly favoring a buy rating.

GeneDx Holdings Corp

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About KeyCorp

With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.

Read more on KEY

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS